Grown Rogue International (GRUSF) Cash from Restructuring (2019 - 2020)
Grown Rogue International's (GRUSF) quarterly Cash from Restructuring came in at -$70425.0 in Q2 2020, down 4.76% quarter-over-quarter from -$67225.0 in Q1 2020.
Grown Rogue International (GRUSF) Cash from Restructuring (2019 - 2020) Analysis & Trends
Grown Rogue International's Cash from Restructuring history runs 2 years deep, the most recent figure standing at -$70425.0 for Q2 2020.
- On a quarterly basis, Cash from Restructuring changed N/A year-over-year to -$70425.0 in Q2 2020; TTM through Apr 2020 was -$407584.0, a N/A change from a year earlier, with the FY2019 full-year figure at $3.5 million, changed N/A from the prior year.
- Cash from Restructuring slipped to -$70425.0 in Q2 2020 per GRUSF's latest filing, from -$67225.0 in the prior quarter.
- Across five years, Cash from Restructuring topped out at $3.7 million in Q1 2019 and bottomed at -$269934.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2020 | -70,425.00 |
| Jan 31, 2020 | -67,225.00 |
| Oct 31, 2019 | -269,934.00 |
| Jan 31, 2019 | 3.72 Mn |